Rifaximin

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.

Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The September 2010 monograph topics are on buprenorphine transdermal system, cabazitaxel, memantine extended-release, mometasone furoate and fomoterol fumarate inhalation aerosol, and alpha₁-proteinase inhibitor (human). The DUE/MUE is on buprenorphine transdermal system.

Get full access to this article

View all access options for this article.

References

Xifaxan [package insert]. Raleigh, NC: Salix Pharmaceuticals Inc; March 2010.

Bass

N.M.

, Mullen

K.D.

, Sanyal

Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010; 362(12): 1071–1081.

Bajaj

J.S.

Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther. 2010; 31(5): 537–547.

Drug Facts and Comparisons. Facts & Comparisons [database online]. St. Louis, MO: Wolters Kluwer Health Inc; 2010. Accessed April 10, 2010.

Gillis

J.C.

, Brogden

R.N.

Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs. 1995; 49(3): 467–484.

Hoover

W.W.

, Gerlach

E.H.

, Hoban

D.J.

, Eliopoulos

G.M.

, Pfaller

M.A.

, Jones

R.N.

Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis. 1993; 16(2): 111–118.

Descombe

J.J.

, Dubourg

, Picard

, Palazzini

Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res. 1994; 14(2): 51–56.

Rizzello

, Gionchetti

, Venturi

Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol. 1998; 54(1): 91–93.

Williams

, James

O.F.

, Warnes

T.W.

, Morgan

M.Y.

Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol. 2000; 12(2): 203–208.

10.

Miglio

, Valpiani

, Rossellini

S.R.

, Ferrieri

Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin. 1997; 13(10): 593–601.

11.

Neff

G.W.

, Kemmer

, Zacharias

V.C.

Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc. 2006; 38(10): 3552–3555.

12.

Leevy

C.B.

, Phillips

J.A.

Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci. 2007; 52(3): 737–741.

13.

Huang

, Esrailian

, Spiegel

B.M.

The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Aliment Pharmacol Ther. 2007; 26(8): 1147–1161.

14.

Zeneroli

M.L.

, Venturini

, Stefanelli

Antibacterial activity of rifaximin reduces the levels of benzodiazepine-like compounds in patients with liver cirrhosis. Pharmacol Res. 1997; 35(6): 557–560.

15.

Bucci

, Palmieri

G.C.

Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin. 1993; 13(2): 109–118.

16.

Song

K.H.

, Lee

K.S.

, Kim

M.H.

The clinical efficacy of rifaximin in the treatment of hepatic encephalopathy (comparison with lactulose) [abstract]. Hepatology. 2000; 32: 407.

17.

Paik

Y.H.

, Lee

K.S.

, Han

K.H.

Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J. 2005; 46(3): 399–407.

18.

Puxeddu

, Quartini

, Massimetti

, Ferrieri

Rifaximin in the treatment of chronic hepatic encephalopathy. Curr Med Res Opin. 1995; 13(5): 274–281.

19.

Mas

, Rodes

, Sunyer

; Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003; 38(1): 51–58.

20.

King

, Reynolds

, Connolly

The effect of rifaximin on the pharmacokinetics (PK) of single doses of intravenous (IV) and oral (PO) midazolam in healthy volunteers [abstract]. Clin Pharmacol Ther. 2004; 75: P66.

21.

King

, Marshall

, Connolly

The effect of rifaximin on the pharmacokinetics of a single dose of ethinyl estradiol (EE) and norgestimate in healthy female volunteers [abstract]. Clin Pharmacol Ther. 2004; 75: P96.

22.

Drug details: Xifaxan (NDA 021361). Drugs@FDA Web site. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed April 16, 2010.